danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics 
Welcome,         Profile    Billing    Logout  
 20 Diseases   7 Trials   7 Trials   216 News 


«1234»
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Clinical, Clinical data, Review, Journal:  Early Enteral Nutrition Met Calories Goals Led by Nurse on Improve Clinical Outcome: A Systematic Scoping Review. (Pubmed Central) -  Oct 29, 2021   
    Critically ill patients face challenges in hypercatabolism due to crisis states, as it may lead to malnutrition...The findings show the benefits of the early EN to guide nurses to start the EN as soon as possible after admitted to the Intensive Care Unit or when hemodynamic is stable in order to achieve a daily calorie target regarding the reduced hospitalization, duration of mechanical ventilation, morbidity, and mortality. The synthesized results show the early EN led by a nurse to address the specific needs and the vital role of nutritional support, and also drive the enteral feeding for critically ill patients to reach the calorie target goals in short times to enhance clinical outcomes.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Targeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides. (Pubmed Central) -  Oct 22, 2021   
    Here, we review these emerging approaches, including the development of STAT3 proteolysis targeting chimera (PROTAC) agents, as well as preclinical and clinical studies of chemically stabilized antisense molecules, such as the clinical agent AZD9150. These therapeutic strategies may robustly reduce the cellular activity of oncogenic STAT3 and overcome the historical limitations of less selective small molecules.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Personal Resilience Can Be Well Estimated from Heart Rate Variability and Paralinguistic Features during Human-Robot Conversations. (Pubmed Central) -  Sep 19, 2021   
    To date, psychological resilience-the ability to cope with a crisis and quickly return to the pre-crisis state-has been identified as an important predictor of psychological well-being but has not been commonly considered by AI systems (e.g., smart wearable devices) or social robots to personalize services such as emotion coaching...The results from machine learning models showed that heart rate variability and paralinguistic features were the overall best predictors of personal resilience. Such predictability of personal resilience can be leveraged by AI and social robots to improve user understanding and has great potential for various mental healthcare applications in the future.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Trial completion date, Trial primary completion date, Metastases:  MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) -  Jul 16, 2021   
    P1,  N=212, Active, not recruiting, 
    Trial completion date: Jun 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Oct 2023 Trial completion date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2023 --> Jan 2024
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  Clinical Results of Various Treatments for Retinal Capillary Hemangioma. (Pubmed Central) -  Jun 24, 2021   
    Fluorescein angiography should be used periodically to determine recurrence of the tumor or inflammation, and the appropriate treatment should be repeated as necessary. Moreover, regular systemic screening tests for von Hippel-Lindau disease should be performed in RCH patients to ensure that they have no abnormalities other than in the eye.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery. (Pubmed Central) -  Jun 22, 2021   
    Recently, esketamine has been shown as a viable rescue treatment option in patients in depressive crisis states...Mean plasma concentrations in rats, 24 h post-application of microneedle patches with drug reservoir F3 and LW3, were 0.260 μg/ml and 0.498 μg/ml, respectively. This developmental study highlights the potential success of hydrogel-forming microneedle arrays as a transdermal drug delivery platform for ESK and supports moving to in vivo tests in a larger animal model.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Scientific Hypothesis-testing Strengthens Neuroscience Research. (Pubmed Central) -  Jun 22, 2021   
    Here I propose to adapt methods normally used in meta-analysis across studies to help rationalize this process. This approach offers many direct and indirect benefits for neuroscientists' thinking habits and communication practices.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca
    [VIRTUAL] Identification of a novel immunosuppressive myeloid gene expression signature for clinical biomarker development () -  Mar 11, 2021 - Abstract #AACR2021AACR_337;    
    P1b/2
    This led to a 6-gene ‘de novo’ signature (MRC1, APOE, C1QA, C1QB, MMP9, SPP1) associated with IMC function with highly significant concordance (rS = 0.96; p = 1.2e-11) to IMC abundance.Lastly, we showed that in whole blood baseline samples from HNSCC patients (n=53) treated with danvatirsen + durvalumab [NCT02499328], our ‘de novo’ signature was significantly elevated (p=0.033) in patients with progressive disease compared to complete responders. Application to additional studies will be required to more fully determine its clinical utility.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Psychoanalytic Perspectives on Moral Injury in Nurses on the Frontlines of the COVID-19 Pandemic. (Pubmed Central) -  Jan 21, 2021   
    Mental health professionals need to be aware of the mental minefields that frontline nurses must navigate when providing care that, due to circumstances beyond their control, may be morally ambiguous. Educating nurses about the meaning of their own emotional and psychic responses amid the realities in the field may help to decrease the damaging effects of moral injury.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Breakpoint Analysis for the COVID-19 Pandemic and Its Effect on the Stock Markets. (Pubmed Central) -  Jan 16, 2021   
    This is due to that the health index used in the modeling would not determine the different capacities of the countries analyzed to respond efficiently to the pandemic effect. Therefore, the contagion is the preponderant factor when analyzing the structural breakdown that occurred in the world economy.
  • ||||||||||  [VIRTUAL] HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy (Scientific Program Auditorium) -  Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1797;    
    P2
    Patients received durvalumab in combination with: olaparib (PARPi; Module 1), danvatirsen (STAT3i; Module 2), ceralasertib (ATRi; Module 3), oleclumab (anti-CD73 antibody; Module 5), trastuzumab deruxtecan (HER2 ADC; Module 6), and cediranib (VEGFRi; Module 7)...Enrolment into Modules 1, 2, and 5 is complete, ongoing in Modules 3, 6, and 7, and Module 4 was discontinued with one patient enrolled, when development of vistusertib was stopped...The subgroup of LKB1 selected patients appear to have the lowest 6-month OS and PFS of subgroups in Module 1 (durvalumab + olaparib). An update is scheduled for Q3 2020.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  NeoCOAST: Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Oct 4, 2020   
    P2,  N=80, Active, not recruiting, 
    Adaptive Capacity may contribute most to life domains where the system needs to be retained, preventing it from reaching a crisis state, for example, work burnout. Recruiting --> Active, not recruiting | N=160 --> 80 | Trial completion date: Mar 2022 --> Jan 2021 | Trial primary completion date: Mar 2022 --> Jan 2021
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Differential gene expression analysis of sickle cell anemia in steady and crisis state. (Pubmed Central) -  Jun 15, 2020   
    For crisis-state patients versus healthy individuals, two networks of regulator effects revealed STAT1, CD40LG, TGM2, IRF7, IRF4, and IRF1 acting as upstream regulators, resulting in disease/function outcomes, including engulfment of cells and aggregation of blood cells and inflammation of joints. Our results indicated genes and pathways that can provide clues on the molecular events involved in the severity of sickle cell disease.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Clinical, PK/PD data, Journal:  Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. (Pubmed Central) -  May 9, 2020   
    P1/2
    Interim analysis from an ongoing study (D5660C00016, NCT03421353) has shown the observed steady state concentration from 200 mg flat dose is in agreement with the model predictions. The population PK model could be further utilized in subsequent exposure-response efficacy and safety modelling.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) -  Apr 30, 2020   
    P1,  N=257, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Oct 2023 | Trial primary completion date: Dec 2020 --> Oct 2023
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Review, Journal:  The Role of Psychological and Social Factors in the Relationship between Attachment and Suicide: A Systematic Review. (Pubmed Central) -  Mar 14, 2020   
    Nevertheless, this emergent evidence base indicates that a range of predisposing, precipitating and crisis-state factors may mediate the association between attachment security and suicidality...Longitudinal and experimental designs are required to verify causal pathways, and to investigate whether trait vulnerabilities interact with acute stressors to increase suicide risk. Finally, disorganised attachment has been overlooked so far and should be given greater consideration going forward.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen
    PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_4052;    
    P1
    AZD5153 is a BRD4 inhibitor; administered orally . In summary, PRISM is a unique platform protocol designed to efficiently evaluate targeted agents in R/R aggressive B-cell lymphoma with an emphasis on comprehensive translational and molecular investigations.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Review, Journal:  Targeting STAT3 in Cancer with Nucleotide Therapeutics. (Pubmed Central) -  Nov 3, 2019   
    Both STAT3 decoy and AZD9150 have advanced to clinical testing in humans. Here we will review the current understanding of the structures, mechanisms, and potential clinical utilities of the nucleic acid-based STAT3 inhibitors.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases:  AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer (clinicaltrials.gov) -  Oct 31, 2019   
    P1/2,  N=110, Active, not recruiting, 
    Here we will review the current understanding of the structures, mechanisms, and potential clinical utilities of the nucleic acid-based STAT3 inhibitors. Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Nov 2019 | Trial primary completion date: Mar 2020 --> Nov 2019